COYA•benzinga•
Coya Therapeutics Announces Interim Results Of Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Treatment In Patients With Mild To Moderate Frontotemporal Dementia
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 24, 2025 by benzinga